Mixed Chimeric Transplantation for Primary Amyloidosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00186095|
Recruitment Status : Withdrawn (Closed, never started.)
First Posted : September 16, 2005
Last Update Posted : October 10, 2007
|Condition or disease||Intervention/treatment||Phase|
|Amyloidosis||Procedure: autologous followed by nonmyeloablative allogeneic transplant||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||45 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Mixed Chimeric Transplantation for Primary Amyloidosis|
|Study Start Date :||December 2000|
|Study Completion Date :||September 2006|
- Treatment of patients with nonmyeloablative allogeneic transplant for amyloidosis.
- Toxicity of therapy
- Changes in marrow and serum abnormalities
- Improvement in end-organ function.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186095
|Principal Investigator:||Keith Stockerl-Goldstein, MD||Stanford University|